Innovative Endpoints in Alzheimer’s Disease Clinical Trials
Speaker
Dr. Jort Vijverberg
Neurologist
Dr. Jort Vijverberg is a neurologist at the Brain Research Center and a senior researcher at Alzheimercentrum Amsterdam. He has been the principal investigator on many Alzheimer’s clinical trials and consults with the pharmaceutical industry.
Together with our partner Brain Research Center, we presented the webinar:
Innovative Endpoints in Alzheimer’s Disease Clinical trials.
During this webinar, two experts in the field, Dr. Niels Prins and Dr. Jort Vijverberg discussed the latest clinical and biomarker endpoints.
During this webinar our experts expanded on how we advance clinical drug development for Alzheimer’s disease by touching upon:
> Biomarker-based participant selection;
> inclusion criteria for upcoming AD trials
> Fluid biomarkers as endpoints in your AD trial;
> EEG; a ‘novel’ AD biomarker.
Related webinars
Scrutinizing Primary Endpoints in ALS Clinical Trials: ALSFRS-R, Survival or a Composite?
During this webinar, Leonard van den Berg, MD, PhD (Chairman TRICALS | UMC Utrecht, NL) and Ruben van Eijk MD, PhD (Lead Statistician TRICALS | UMC Utrecht, NL) will discuss Primary endpoints in ALS clinical trials, differences in regulatory requi...
The Alzheimer’s disease drug development landscape
Hosted by: Julius Clinical. Speakers: Pieter van Bokhoven | CSO| IAO Amsterdam Neuroscience AUMC Jort Vijverberg | Neurologist | Amsterdam Neuroscience AUMC Topics that are discussed during this webinar: All major trends in Alzh...
Efficient Patient Identification in ALS Clinical Trials Leveraging the Concept of Fast and Slow Progressors
Together with our partner TRICALS, we presented the webinar: Efficient Patient Identification in ALS Clinical Trials; Leveraging the Concept of Fast and Slow Progressors. During this webinar, Prof. Dr. L.H. van den Berg and R.P.A van Eijk talke...